# Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects

> **NCT00916110** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103

## Key facts

- **NCT ID:** NCT00916110
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916110, "Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00916110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*